GLP-1+GIP vial 15 mg

Tirzepatyd 15mg reagent - characteristics

Tirzepatyd 15mg is a synthetic, long-acting peptide analogue designed to study complex metabolic pathways involved in glucose regulation and incretin signalling. The molecule contains a lipid modification that allows increased binding to plasma albumin, which translates into increased structural stability and extended half-life under experimental conditions. These properties make tirzepatyd 15 mg a stable reagent for laboratory analyses requiring prolonged biological exposure.

Tirzepatyd 15mg - structure and stability

Structurally, tirzepatyd consists of 39 amino acids, and the peptide sequence modifications used increase its resistance to enzymatic degradation. The designed molecular architecture allows the maintenance of a stable pharmacokinetic profile and prolonged biological activity after subcutaneous administration. In experimental studies, these features enable the analysis of long-term biological effects with limited frequency of administration, making tirzepatyd 15mg a useful tool for metabolic studies.

Check also the reagent SLU-PP-332 500mcg/60 capsules 

Tirzepatyd 15mg - mechanism of action at the receptor level

At the receptor level, tirzepatyd 15 mg shows concomitant affinity for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Under research conditions, activation of these pathways is observed to promote increased insulin secretion in a glucose-dependent manner and modulation of glucagon secretion, supporting analyses of the regulation of the carbohydrate metabolism and satiety axis. The effects on the gastrointestinal tract, including the slowing of gastric emptying and modulation of satiety signals, are the focus of further observations by researchers in the context of studies on energy supply control and body weight changes in research models. In randomised controlled clinical trials, researchers analysed the long-term effects of exposure to tirzepatyd at different dosing regimens, including the 15 mg dose. Observations were made on the maintenance of changes in selected metabolic parameters and the substance's tolerance profile with prolonged exposure. The results of these studies indicate a stable biological response and a predictable safety profile, confirming the suitability of tirzepatydu 15mg as a research tool in the analysis of long-term metabolic processes.

Source:

The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.